299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

8 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03756922 (ClinicalTrials.gov)	November 27, 2018	27/11/2018	A DDI Study of FDL169 and FDL176 in Healthy Subjects	A Phase 1/2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR Mutation	Cystic Fibrosis	Drug: FDL169;Drug: FDL176	Flatley Discovery Lab LLC	NULL	Suspended	18 Years	55 Years	All	78	Phase 1/Phase 2	United Kingdom
2	NCT03527095 (ClinicalTrials.gov)	April 5, 2018	4/5/2018	A Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects	A Phase 1, Open-label, Randomised, Cross Over Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects Following Single Doses	Cystic Fibrosis	Drug: FDL169	Flatley Discovery Lab LLC	NULL	Completed	18 Years	55 Years	All	11	Phase 1	United Kingdom
3	NCT03516331 (ClinicalTrials.gov)	March 7, 2018	24/4/2018	A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects	A Phase 1, Open Label, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects	Cystic Fibrosis	Drug: FDL176 & FDL169 coadministration	Flatley Discovery Lab LLC	NULL	Completed	18 Years	55 Years	All	16	Phase 1	United Kingdom
4	NCT03424252 (ClinicalTrials.gov)	December 18, 2017	31/1/2018	An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects	A Phase 1, Open-label, Crossover, Randomised Study to Evaluate the Pharmacokinetic Profile of FDL169 Sublingual Formulations in the Fed State in Healthy Subjects	Cystic Fibrosis	Drug: FDL169	Flatley Discovery Lab LLC	NULL	Completed	18 Years	55 Years	All	11	Phase 1	United Kingdom
5	NCT03093714 (ClinicalTrials.gov)	August 23, 2017	16/3/2017	A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects	A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Safety, Pharmacokinetics (PK) and Pharmacodynamics(PD) of FDL169 in Cystic Fibrosis (CF) Subjects Homozygous for the F508del-CFTR Mutation	Cystic Fibrosis	Drug: FDL169;Drug: Placebo	Flatley Discovery Lab LLC	NULL	Completed	18 Years	85 Years	All	27	Phase 1	Australia;Czechia;Germany;United Kingdom
6	NCT02767297 (ClinicalTrials.gov)	April 2016	5/5/2016	Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis	A Three-Part Phase 1b Bioavailability and Pharmacokinetics Study of Two Formulations of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis	Cystic Fibrosis	Drug: FDL169	Flatley Discovery Lab LLC	NULL	Completed	18 Years	N/A	Both	46	Phase 1/Phase 2	United Kingdom
7	NCT02680418 (ClinicalTrials.gov)	December 2015	2/2/2016	Pharmacokinetics of FDL169 in Healthy Female Subjects	A Phase I Dose Escalation Study to Assess the Pharmacokinetics (PK) of FDL169 in Healthy Female Volunteers	Cystic Fibrosis	Drug: FDL169	Flatley Discovery Lab LLC	NULL	Completed	18 Years	55 Years	Female	8	Phase 1	United Kingdom
8	NCT02359357 (ClinicalTrials.gov)	January 2015	13/1/2015	FTIH - Single and Repeat Oral Doses of FDL169 in Healthy Volunteers	A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation First-Time-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeat Oral Doses of FDL169 in Healthy Volunteers	Cystic Fibrosis	Drug: FDL169;Drug: Placebo	Flatley Discovery Lab LLC	NULL	Completed	18 Years	45 Years	Male	130	Phase 1	United Kingdom